Medical Coverage Policy

Effective Date: 2/15/2021
Next Review Date: 2/15/2022
Coverage Policy Number: 0118

Bone, Cartilage and Ligament Graft Substitutes

Table of Contents

Overview .............................................................. 1
Coverage Policy ................................................... 1
General Background ............................................ 3
Medicare Coverage Determinations ............. 17
Coding/Billing Information ......................... 17
References ..................................................... 21

Related Coverage Resources

Autologous Platelet-Derived Growth Factors (Platelet-Rich Plasma [PRP])
Bone Growth Stimulators: Electrical (Invasive, Noninvasive), Ultrasound
Intervertebral Disc (IVD) Prostheses
Lumbar Fusion for Spinal Instability and Degenerative Disc Conditions, Including Sacroiliac Fusion
Minimally Invasive Spine Surgery Procedures and Trigger Point Injections
Percutaneous Vertebroplasty, Kyphoplasty and Sacroplasty
Stem Cell Therapy for Orthopaedic Applications
Tissue-Engineered Skin Substitutes

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Overview

This Coverage Policy addresses bone graft substitute and other orthobiologic-type materials. The materials in scope of this Medical Coverage Policy include bone graft substitutes, bone void fillers, articular cartilage materials, recombinant morphogenetic proteins, and ligament and meniscus reconstruction materials.

Coverage Policy

The effectiveness of some bone graft materials, including those that undergo advanced processing methods, has not been demonstrated as clinically superior to those which do not undergo advanced processing methods. Bone graft substitutes that undergo advanced processing methods are often more costly. Many health plans administered by Cigna contain definitions of medical necessity which include a cost comparison component. When medical necessity criteria have been met, coverage of a bone graft
substitute may be limited to the lowest cost, clinically equivalent alternative. Please refer to the applicable plan document to determine benefit availability and the terms, conditions and limitations of coverage.

Dental implants are specifically excluded under many benefit plans. When coverage for dental implants is excluded, the use of bone graft materials in conjunction with a dental implant, including sinus and/or alveolar ridge augmentation, is similarly not covered.

Bone Graft Materials/Substitutes
The following bone graft materials and/or substitutes, used alone or in combination, are each considered medically necessary for enhancement of bone healing:

- autografts
- allograft-based, including demineralized bone matrix (DBM)
- ceramic or polymer-based synthetic bone graft substitutes
- bone graft substitutes containing anorganic bone material (e.g., bovine, coral) when used alone or combined with another covered bone graft substitute

The following bone graft materials and/or substitutes are each considered experimental, investigational or unproven for the enhancement of bone healing:

- human amniotic membrane bone graft substitute materials, including amniotic fluid stem cell substitutes
- cell-based substitutes (e.g., mesenchymal stem cells used alone, added to other biomaterials for grafting, or seeded onto scaffolds)
- human growth factor substitutes (e.g., fibroblast growth factor, insulin-like growth factor)
- bone marrow aspirate processed to concentrate growth factors (e.g., concentrated bone marrow aspirate, centrifuged bone marrow aspirate), used alone or in combination with other bone graft materials (e.g., allograft)
- bone graft substitutes containing anorganic bone material (e.g., bovine, coral) when used alone or combined with another covered bone graft substitute
- allograft bone graft substitutes used exclusively as stand-alone stabilization devices for fusion (e.g., TruFuse® for isolated facet fusion, NuFix™ for isolated facet fusion, BacFast® HD for isolated facet fusion)
- bone graft substitutes used to reduce donor site morbidity (e.g., iliac crest donor site reconstruction)

Recombinant Bone Morphogenetic Protein (rhBMP)
rhBMP-2 (i.e., INFUSE® Bone Graft) is considered medically necessary when criteria is met for EITHER of the following conditions:

- In combination with a fusion device for a single-level anterior interbody lumbar or lumbosacral fusion* surgery when ALL of the following criteria have been met:
  - degenerative disc disease at one level from L2–S1
  - no more than Grade I spondylolisthesis at the involved level
- In surgical repair of an acute, open tibial shaft fractures when BOTH of the following criteria are met:
  - fracture is stabilized with intramedullary (IM) nail fixation
  - rhBMP–2 is applied within 14 days of the fracture

*Note: For specific medical necessity criteria for lumbar fusion please reference the Cigna Lumbar Fusion for Spinal Instability and Degenerative Disc Conditions Coverage Policy.

rhBMP–2 is considered experimental, investigational or unproven for ALL other indications, including the following:
• rhBMP–2 (i.e., INFUSE® Bone Graft) when used for spinal fusion procedures other than single-level anterior spinal fusion (e.g., posterior lumbar fusion, transforaminal lumbar fusion, more than single-level fusion)
• rhBMP–2 (i.e., INFUSE® Bone Graft) as an alternative or adjunct treatment for sinus augmentation and/or localized alveolar ridge augmentation
• rhBMP–2 (i.e., INFUSE® Bone Graft) for the treatment of cervical spine conditions

rhBMP-7 (i.e., OP–1™) is considered experimental, investigational or unproven for ALL indications.

**Ligament/Meniscus Reconstruction**

The following are each considered experimental, investigational or unproven when used alone or as part of a ligament or meniscus reconstruction, regeneration, or transplantation:

• bioactive scaffolds (e.g., collagen meniscal implants)
• bioresorbable porous polyurethane
• meniscal prosthesis
• tissue-engineered menisci
• xenografts

**Bone Filler / Articular Cartilage**

The following bone filler and/or articular cartilage materials are each considered experimental, investigational, or unproven:

• synthetic resorbable polymers (e.g., PolyGraft™ BGS, TruFit® [cylindrical plug], TruGraft™ [granules])
• juvenile cartilage allograft tissue implantation, including minced cartilage (e.g., DeNovo® NT Natural Tissue Graft, DeNovo® ET™ Engineered Tissue Graft [ISTO Technologies, Inc., St. Louis, MO / Zimmer, Inc., Warsaw IN]; BioCartilage® [Arthrex, Naples, Florida])
• decellularized osteochondral allograft implant (e.g., Chondrofix® Osteochondral Allograft [Zimmer Biomet, Warsaw, IN])

**General Background**

Bone grafts can be harvested from the patient (autograft), a cadaver (allograft), or they can be synthetic. The composition of allograft and synthetic bone graft substitutes and their mechanism of action can vary widely. Bone graft materials are often combined to extend graft availability and enhance healing. Used alone or in combination, bone graft substitutes may be utilized for many orthopaedic applications including spinal fusion, for enhancement of fracture healing, for filling cavities and defects, bridging joints, establishing the continuity of long bone and providing bone blocks. More recently, bone graft materials such as calcium phosphate and bioglass combined with antibiotics are being investigated as a method of delivering antimicrobials to the site of infection, such as for treatment of osteomyelitis, although additional studies are needed to support safety and efficacy.

For most of the indications noted above, there is sufficient evidence to support safety and effectiveness, although for some indications clinical studies are limited, for others there is no evidence, and for some types of materials, clinical studies are not required. Many of the bone graft substitute products are regulated by the United States Food and Drug Administration (FDA). For example, nonstructural allograft and cellular allograft materials are considered human cells, tissues and cellular tissue-based products and as such do not require preclinical or clinical data by the FDA. Synthetic bone grafts and demineralized bone matrices (DBM) are considered Class II materials and fall under the FDA 510(k) regulatory process and upon approval are considered “substantially equivalent” to another marketed device/material used for the same purpose. Other materials, such as those that are considered drug-device combinations require premarket approval (PMA); FDA PMA approval requires an investigational device exemption clinical trial prior to the PMA application (Abjornson, et al., 2018).
Autografts are considered the established standard graft material and are typically retrieved from the patient’s tibia, fibula, ileum or iliac crest, by way of a surgical procedure and are then placed at the injury site. The advantage of autograft is the high probability of success—autograft possesses all of the necessary characteristics such as osteoconductivity, osteogenicity, and osteoinductivity. The disadvantages associated with autografts are that the amount of autogenous bone available for grafting is limited; autografts are associated with increased morbidity; increased anesthesia time and blood loss; and post-operative donor site complications.

The iliac crest is the most common site for autograft harvesting. Once the actual bone graft is obtained the site is allowed to heal independently without backfilling. However, there is often post-operative harvest site pain associated with this procedure. The use of various bone graft substitutes are being investigated for backfilling of iliac crest harvest sites, particularly when used for spinal surgery, as a method of reducing pain and for improving cosmesis. Despite this proposed use there is insufficient data in the peer-reviewed published scientific literature supporting the effectiveness of iliac reconstruction with any type of graft material. Most of the published studies involve small sample populations with inconsistent clinical outcomes for reducing donor site morbidity. The use of bone graft substitutes for this indication is not recommended at this time due to lack of data supporting safety, efficacy and improved clinical outcomes.

Autologous bone marrow aspirate obtained from the iliac crest is also commonly used during orthopedic procedures as an adjunct to other graft materials to enhance bone healing. Freshly harvested bone marrow aspirate contains osteogenic precursor cells (mesenchymal stem cells, growth factors) and once aspirated may be injected directly into defects or mixed with other grafting materials. In theory, combining bone marrow aspirate with an osteoconductive and osteoinductive bone graft material will avoid associated disadvantages of iliac crest graft harvest and improve healing. Although injecting aspirate directly into defects or mixing with other allograft materials is commonly performed, it is considered integral to the surgical procedure.

Another proposed use of bone marrow is aspirate involves various cell retention and processing methods which are now being utilized to increase cell concentration. It has been suggested that stem cell concentration is directly related to overall effectiveness and as a result, in order to increase the concentration of osteoprogenitor cells various cell retention processing methods (e.g., centrifugation) may be employed. Although the amount of aspirate required and proposed indications vary, the process has also been referred to as bone marrow nucleated cell concentrate (BMAC) or autologous bone marrow mononuclear cells (BMMC). The techniques for concentrating bone marrow aspirate vary, as well as the resulting cell concentration and cell viability. Comparative data in the medical literature is insufficient to support clinical effectiveness of concentrated bone marrow aspirate and strong evidence based conclusions cannot be made at this time.

Allografts

One alternative to autograft is the use of allografts. Allograft offers the advantage of avoiding additional surgery and potential complications associated with harvesting host bone during the primary procedure. Allograft materials are frequently used during various orthopedic procedures, and may also be used alone or in combination with other materials. Allografts are readily available from bone banks and provide both osteoinductive and osteoconductive (e.g., structural support) properties, however they lack osteogenic properties. Allografts may give less consistent clinical results, and there may be an increased risk of disease transmission and immunogenic response. When allografts are intensively processed to decrease these risks, the osteoinductive potential is lessened, and the processing removes osteogenic cells and reduces mechanical strength. AlloGro® Demineralized Bone Matrix (Wright Medical, Arlington, TN); Dynagraft-D™ (Citagenix, Laval, Quebec, Canada); Opteform® (Exactech, Inc., Gainesville, FL); Grafton® (Osteotech, Eatontown, NJ); OrthoBlast (IsoTis Orthobiologics, Irvine, CA); TruFuse® (minSURG™ Corp., Clearwater, FL); and NuFix™ (Nutech Medical, Birmingham, AL) are examples of allograft-based bone graft substitutes.

With improved processing methods some allograft products are now available that manufacturers claim retain higher concentrations of naturally occurring growth factors and/or stem cells. Human growth factors such as fibroblast growth factor, insulin-like growth factor, platelet-derived growth factor, transforming growth factor-beta, and microglobulin-B, are examples of osteogenic growth factors that are naturally found within the matrix of bone. Despite availability and current use, clinical superiority has not been demonstrated in the medical literature supporting the use of these materials. How these allograft bone graft materials, processed to retain higher
concentrations of inherent growth factors and/or stem cells, improve the rate and quality of bone formation compared to other available allograft bone graft substitutes, has not yet been firmly established.

Demineralized bone matrix (DBM) is also a type of allograft. It is produced through a process that involves the decalcification of cortical bone; substantially decreasing the structural strength. However, it is more osteoinductive than ordinary allograft. Although the reason for this is not completely understood, it has been speculated that the osteoinductive growth factors contained in the extracellular bone matrix are more easily accessed once the mineral phase of the bone has been removed. Allograft DBM preparations available for use include Osteotech’s Grafton®, Regeneration Technology’s Osteofil® and Medtronic’s Magnifuse to name a few. These preparations differ in shape and size of DBM particles, the amount of inherent growth factors, the amount of residual minerals, and the type of carrier materials.

**Anorganic Bone Graft Materials**
Anorganic bone graft material is a type of xenograft bone graft substitute made from other than human material, such as cow (i.e., bovine) or coral, and is typically used in combination with other types of bone graft materials, for example with collagen or a calcified matrix. The animal bone is processed to remove any organic components (i.e., anorganic bone material) reducing concerns of disease transmission or immunogenic reactions. Some of the anorganic type xenograft materials (e.g., Bio-Oss) may be used as stand-alone graft material to enhance healing, such as when used for dental implants. When used according to U.S. Food and Drug Administration (FDA) approved indications, either alone or combined with other bone graft materials proven effective, anorganic bone graft materials are considered safe and effective for promoting bone formation.

**Bone Graft Substitutes**
Due to the limitations of autogenous bone and allograft material, and the number of surgeries that require grafting, investigators have developed grafting alternatives, some of which are available for current use and others which are still in developmental stages. Bone graft substitutes have overlapping properties and are often made of a variety of materials such as polymers (degradable and nondegradable), ceramics and composites (calcium phosphate, calcium sulfate, and bioactive glass), factor-based materials (recombinant growth factors) and cell-based materials (mesenchymal stem cells). Some authors classify bone graft substitutes according to these materials. However, these substitutes can also be classified based on their characteristics, such as osteoconduction (e.g., calcium sulfate, ceramics, calcium phosphate, cements, collagen), osteoinduction (e.g., DMB, rhBMPs, growth factors), osteogenesis (e.g., bone marrow aspirate), or combined (composites). Nonetheless, the ideal bone graft substitute must provide scaffolding for osteoconduction, growth factors for osteoinduction and progenitor cells for osteogenesis. In addition, the bone graft substitute must be able to integrate with the host.

The role of bone graft substitutes is to provide a medium for osteoconduction rather than osteoinduction and can provide variable levels of structural support. These materials appear to be safe when used according to FDA indications; however each type of product is under varying degrees of regulation and in some cases safety and efficacy of these products remain unproven through human trials. For the intent of this coverage policy, bone graft substitutes are described as those that are cell-based, ceramic-based, polymer-based and factor-based. Synthetic substitutes generally consist of ceramic and polymer based materials.

**Cell-based:** Bone graft substitutes that are cell-based use cells to generate new tissue either alone, with other biomaterials, or seeded onto a support matrix (e.g., in combination with allograft material). Support matrix materials may include xenograft (i.e., bovine) or human type I collagen. Examples of cell-based substitutes include but are not limited to:

- **Mesenchymal stem cells (MSCs):** MSCs are multipotent stem cells that express a variety of different cell surface proteins and can differentiate into a variety of cell types, such as osteoblasts, chondrocytes, myocytes, adipocytes, and neuronal cells. Although processing techniques vary, and the optimal number of MSCs to be transplanted/seeded has not been established, following autologous bone marrow collection MSCs are either concentrated for direct injection, or cultured and incubated. Once cultured the MSCs can be mixed with biomaterials, such as gels or pastes; the biomaterials hold the cells in suspension and provide a matrix for filling defects. MSCs can also be seeded on scaffolds, and have been investigated when used with a support matrix for implantation (e.g., tissue engineered). In theory, MSCs are responsive to osteogenic growth factors and aid in the healing of bone. Nevertheless
evidence in the published peer-reviewed scientific literature evaluating the use of MSCs to enhance bone healing consists mainly of animal trials and a paucity of human trials. At present the evidence is insufficient to support improved clinical outcomes, when used alone, added to other biomaterials, or as cultured/seeded on a support matrix.

- Trinity® Evolution™ (Orthofix®, Inc., Lewisville, TX) is a viable cell allograft that according to the manufacturer contains active adult mesenchymal stem cells. Trinity Evolution contains osteoprogenitor cells, mesenchymal stem cells, and demineralized cortical bone to promote osteoconduction, osteogenesis, and osteoinduction for successful bone grafting.

- Osteocel® Plus (NuVasive, Inc, San Diego, CA) is an allograft cellular matrix that contains viable stem cells. The manufacturer suggests this material promotes fusion in cervical, thoracic, and lumbar procedures. According to the manufacturer, Osteocel Plus mimics the biologic properties of autograft and contains mesenchymal cells, cancellous bone, and demineralized bone matrix. Osteocel Plus also provides a scaffold for new bone to grow on, theoretically avoiding limitations of other more traditional bone graft alternatives.

- Amniotic membrane, the innermost layer of the fetal membrane, is considered a source of collagen that acts as a scaffold for the attachment of cells. Recently, amniotic membrane allografts have been investigated for various uses including use as bone void fillers during spinal and other orthopedic surgeries to enhance bone healing. Classifications of these products differ depending on the specific product but are generally classified as human tissue and/or cell-based products. Some are claimed to be non-immunogenic by the manufacturer. Amniotic membrane allografts currently under investigation include NuCell® (Nutech Medical, Birmingham, AL, USA), Ovation® cellular repair matrix (Osiris Therapeutics, Inc., Columbia, MD, USA) derived from placental mesenchyme to name a few. In addition, amniotic fluid stem cells, derived from amniotic fluid, are being investigated to form tissue-engineered bone from scaffolds in animal trials; human trials are ongoing but limited.

The use of mesenchymal and other cell-based bone graft substitutes has been and continues to be investigated for various procedures, including spinal fusion, intervertebral disc regeneration and other orthopedic procedures. Although currently under investigation, data published in the medical literature supporting safety and efficacy for these indications are lacking.

**Ceramic-based:** Ceramic-based bone graft substitutes include materials such as calcium phosphate, calcium sulfate and bioactive glass, used alone or in combination with other grafts. Some ceramic-based products (e.g., calcium phosphate-collagen composites, beta-tricalcium phosphate) are combined with collagen to augment healing; collagen composites may include bovine material similar to that used with cell-based products. Several types of calcium phosphates, including tricalcium phosphate, synthetic hydroxyapatite, and coralline hydroxyapatite are available in pastes, putties, solid matrices, and granules. When used, calcium sulfate is less desirable for weight bearing applications due to loss of mechanical properties during degradation. When implanted into living tissue, bioactive glass forms a bond with pre-existing bone, however there are only a few products commercially available and use is primarily in dental applications. Synthetic hydroxyapatite (e.g., ProOsteon® Implant 500 [Interpore Cross, Int., Irvine, CA]) is brittle, has little tensile strength and is typically used for bone defects with internal fixation. A pure beta-tricalcium phosphate scaffold, Vitos® Synthetic Cancellous Bone Filler (Orthovita, Inc., Malvern, PA) is intended for use in small defects in the extremities, pelvis, and spine. Other ceramic-based materials include but are not limited to:

- Osteograf® (Ceramed, Lakewood, CO)
- Norian SRS (Skeletal Repair System) (Synthes, Inc., West Chester, PA)
- Osteoset® (Wright Medical, Arlington, TN)
- Actifuse™ (ApaTech Limited, Elstree, Hertfordshire, UK)
- Integra MOZAIK™ Osteoconductive Scaffold (Integra LifeSciences, Plainsboro, NJ)
- PRO-DENSE® Bone Graft Substitute paste(Wright Medical Technology, Inc., Arlington, TN)

Subchondral injection of calcium phosphate bone substitute, into the area of subchondral bone edema, as part of treatment for osteochondritis dissecans of the knee, and other joints has been reported in the literature (Levy, Cousins, 2020; Bonadio, et al., 2017; Cohen, Sharkey, 2016; Abrams, et al., 2013). Conservative treatment of osteoarthritis-related bone marrow lesions generally includes pain control, reduction in weight bearing, activity modification, and appropriate nutrition including additional calcium and vitamin D during treatment if appropriate.
One procedure aimed at treating such defects, the Subchondroplasty® (SCP®) procedure (Zimmer Holdings, Inc.; Warsaw, IN), is a minimally invasive surgery designed to access and treat bone defects associated with chronic bone marrow lesions by filling them with a biomimetic bone substitute material.

Nairn et al. (2020) published the results of a systematic review evaluating safety and early results of Subchondroplasty® for the treatment of bone marrow lesions. The authors review included 17 studies, all studies were graded as level 4 evidence except one which was graded level 3. The review included 756 subjects in total, 13 studies investigated use for the knee and four evaluated use for foot and ankle joint pain related to a bone marrow lesion. Mean pain scores using VAS improved postoperatively (7.8 +/- 0.6 to 3.4 +/- 0.7), functional scores improved when reported (IKDC 31.7 ± 1.9-54.0 ± 4.2 and KOOS 38.1 ± 0.6-70.0 ± 4.1) and there were high levels of patient satisfaction postoperatively. Complications occurred in seven cases, most seriously osteomyelitis and avascular necrosis. In addition, the authors reported that the rate at which subjects converted to arthroplasty ranged from 12.5 to 30% with followup ranging from 10 months to seven years. In the author’s opinion, low quality studies supported a reduction of pain, improved function, high patient satisfaction and a subsequent delay in more invasive procedures. However additional high quality studies with long term followup are required to determine any impact to clinical practice recommendations.

Evidence in the peer reviewed scientific literature evaluating injection of a calcium phosphate bone substitute into the area of subchondral bone edema, or of the Subchondroplasty® procedure, in the treatment of chronic bone marrow lesions / bone marrow edema is lacking. As a result, evidence based conclusions regarding safety, efficacy, and impact on health outcomes cannot be firmly established.

**Polymer-based:** Polymer-based substitutes are polymers that are either degradable or nondegradable and may be used alone or in combination with other materials. Degradable polymers are resorbed by the body allowing it to heal itself without foreign bodies remaining. Types of polymer-based substitutes include but are not limited to:
- Cortoss® (Orthovita, Inc., Malvern, PA [Stryker])
- OPLA (TMH Biomedical, Inc., Duluth, MN)
- Immix (OsteoBiologics, Smith and Nephew, Memphis, TN).

**Factor-based:** Factor-based bone graft substitutes consist of human growth factors and recombinant growth factors used alone or in combination with other materials. Factor-based osteogenic bone graft substitutes include but are not limited to:
- human growth factors (e.g., fibroblast growth factor, insulin-like growth factor, transforming growth factor-beta), used alone or in combination with other materials
- recombinant bone morphogenetic proteins (rhBMP), used as an adjunct to autografts

**Human Growth Factors**
Fibroblast growth factor (FGF), insulin-like growth factor (ILGF), transforming growth factor-beta (TGF-beta) and bone morphogenetic protein (BMP) are human growth factors found in the matrix of bone. Some of these factors have been isolated in research settings for use alone or in combination with other materials; however evidence in the published, peer-reviewed scientific literature is insufficient to support safety and efficacy at this time.

**Recombinant Bone Morphogenetic Proteins (rhBMP)**
RhBMP is a unique subgroup of graft substitutes and many published trials support safety and efficacy. The function of BMP is to promote differentiation of mesenchymal cells into chondrocytes and osteoblasts, to promote differentiation of osteoprogenitors into osteoblasts, and to influence skeletal pattern formation.

Recombinant human bone morphogenetic proteins act as an adjunct to autogenous bone grafts, and are used commonly with spinal instrumentation devices (i.e., cages) during lumbar fusion and for fracture repair. According to the FDA, (FDA, 2008) safety and effectiveness of rhBMP for the treatment of cervical spine conditions has not been demonstrated.

RhBMP–2 appear to be safe when used appropriately, placed accurately, not allowed to come into contact with decompressed areas (i.e., rhBMP carrier must be protected from compression to avoid the forcing out of implant into surrounding tissues) and contained in the region of surgical fusion. BMPs must be used with caution in the presence of defects in the dura. In spinal fusion surgery, BMP cannot resist compression or shear forces within a
vertebral motion segment; thus, they cannot be used as stand-alone devices. RhBMP–2 must be used with a cage or some type of supportive structure within the vertebral interspace.

The benefits of rhBMP versus autogenous iliac crest bone graft (AICBG) are the decreases in operating room time, blood loss, and morbidity due to the avoidance of an additional procedure to harvest AICBG. None of the early studies utilizing rhBMP–2 or rhBMP–7 documented any adverse systemic effects occurring as a result of their use. A small percentage (≤10%) of patients develops antibodies to rhBMPs, although there has been no documented evidence of harm resulting from this. Carreon et al. (2008) studied wound related and anaphylactic related adverse events in a case series of patients (n=90) who were re-exposed to rhBMP-2 and reported that multiple exposures from either a secondary primary surgery or revision (through the same approach or a different approach) does not increase the risk of those adverse events.

Although early evidence supports safety and efficacy when used according to FDA indications, adverse events have been reported which include ectopic bone formation, bone resorption or remodeling at the graft site, hematoma, neck swelling, and painful seroma (Benglis, et al., 2008). Dural tears, bowel/bladder and sexual dysfunction, failure to fuse and paralysis have also been reported (Epstein, 2011), as well as carcinogenicity and teratogenic effects. Recently there has been concern more specifically safety and efficacy of rhBMP–2 used in spinal fusion surgeries. According to Carragee, et al. (2011), who in a systematic review compared conclusions regarding safety and efficacy published in the original rhBMP–2 industry-sponsored trials when used for spinal fusion, to data published following the FDA approval, the risk of adverse events associated with rhBMP–2 for spinal fusion was found to be “10 to 50 times the original estimates calculated from the industry-sponsored peer-reviewed publications.”

As a result of reported complications and the recent concern regarding safety and efficacy, use of RhBMP–2 product should be limited to the FDA-approved labeling indications. Evidence in the peer-reviewed scientific literature is insufficient and does not provide strong support to safety and efficacy of rhBMP–7 to enhance bone healing.

RhBMP–2/ INFUSE® Bone Graft
RhBMP–2 is marketed in the U.S. as INFUSE® Bone Graft in conjunction with specific spinal and non-specific tibial fusion devices, as an alternative to autogenous bone graft for sinus augmentation, and for localized alveolar ridge augmentation for defects associated with extraction sockets.

Anterior Lumbar Spinal Fusion: The FDA gave new device approval to the InFuse™ Bone Graft/LT-CAGE™ (Medtronic Sofamor Danek, Memphis, TN) in July 2002. The InFuse Bone Graft /LT Cage is intended to be implanted via an anterior open or an anterior laparoscopic approach. According to the FDA approval, safety and effectiveness for approaches other than anterior have not been established. In December 2003 the approval was broadened to include additional fusion cages, specifically the INTER FIX™ Threaded Fusion Device and the INTER FIX™ RP Threaded Fusion Device (FDA, 2004). The device is to be used by surgeons experienced in spinal fusion surgery and adequately trained in the use of the device.

The use of these devices in conjunction with surgical spinal fusion has been approved by the FDA, with numerous supplements to the original PMA, for patients who meet all of the following criteria:

- skeletally mature
- degenerative disc disease at one level from L2–S1
- no more than Grade I spondylolisthesis at the involved level
- failure of at least six months of nonoperative therapy

The device is contraindicated in patients with the following conditions:

- hypersensitivity to rhBMP–2, bovine Type I collagen or to other components of the formulation
- resected or extant tumor at the operative site
- active infection at the operative site
- allergy to titanium or titanium alloy
• possible or confirmed pregnancy

Evidence in the published peer-reviewed scientific literature consists of case series, randomized control trials, and literature reviews, many of which demonstrate safety and efficacy for the use of rhBMP–2 during spinal fusion (Burkus, et al., 2005; Glassman, et al., 2005; Baskin, et al., 2003; Burkus, et al., 2002; Kleeman, et al., 2002). In general, sample populations vary in size from 11 subjects to as many as 279 subjects and follow-up periods range from six to 24 months. Most of the patients have single-level lumbar disc disease. The approach to lumbar fusion and the use of instrumentation varies among clinical trials. Most of the control groups had standard lumbar fusion using autograft bone from the iliac crest. The results of early clinical trials (Boden, et al., 2000; Boden, et al., 2002; Burkus, et al., 2005) demonstrate that patients who received rhBMP–2 during spinal fusion surgery had shorter operating room times, shorter length of stay, and less blood loss compared to patients who received autogenous bone graft. Several studies published since that time has demonstrated similar results.

**Posterior Spinal Fusion:** RhBMP-2 has been used as part of posterior fusion techniques for treating both single and multi-level spinal deformity, either alone or combined with other osteoconductive scaffolds, and some authors have reported improved clinical outcomes (e.g., earlier and higher fusion rates) compared to iliac crest bone graft (Dawson, et al., 2009; Dimar, et al., 2009; Mulconrey, et al., 2008; Luhmann, et al., 2005). However, this represents an off-label use as it is not FDA-approved for posterolateral, posterior lumbar interbody fusion or multilevel fusion.

**Cervical Spinal Fusion:** Although it is an off-label use, rhBMP–2 has been evaluated for use in cervical spinal fusion. In 2006, Smucker et al. conducted a retrospective case-control study comparing the incidence of perioperative cervical swelling complications after anterior cervical fusion with (n=69) or without the use of rhBMP–2 (n=165). The authors found that rhBMP–2 was significantly associated with increased cervical swelling and reported that 27.5% (19 of 69) of the rhBMP–2 group had a clinically significant swelling event compared to 3.6% in the non-rhBMP–2 group. The results were statistically significant (p<0.001). Boakye et al. (2005) retrospectively reviewed outcomes in 24 consecutive patients who had undergone anterior cervical discectomy and fusion of one to three levels using polyetheretherketone (PEEK) spacers filled with rhBMP–2. Fusion was documented by radiograph in all cases, and clinical outcomes were rated as good to excellent in 95% of cases. Complications included transient recurrent laryngeal nerve injury in one case, transient C–5 paresis in one, cerebrospinal fluid leakage in one, and transient dysphagia in two. Further clinical trials are required to support safety and efficacy for treatment for cervical spine conditions.

**Fracture Repair:** RhBMP–2 has also been studied in patients with tibial fractures; this application received premarket approval from the FDA in April 2004. It is marketed as the INFUSE® Bone Graft device (Wyeth Pharmaceuticals, Inc., Philadelphia, PA) and consists of rhBMP–2 in an absorbable collagen sponge. The FDA approval for this device is for the treatment of patients with acute, open tibial shaft fractures when all of the following criteria are met:

- The fracture must be stabilized with intramedullary (IM) nail fixation after appropriate wound management.
- The rhBMP–2 must be applied within 14 days after the initial fracture.
- The prospective patient should be skeletally mature.

The FDA notes the following contraindications to use of the product:

- possible or confirmed pregnancy
- sensitivity to titanium, titanium alloy, cow (bovine) Type I collagen, or rhBMP–2
- infection near the area of the surgical incision
- previous or current tumor at the site of use
- high risk of amputation of the affected leg
- compartment syndrome of the affected leg
Published clinical studies evaluating the use of rhBMP–2 in patients with tibial fractures support safety and efficacy (Swiontkowski, et al., 2006; Jones, et al., 2006; Govender, yet al., 2002).

**Sinus Augmentation/Alveolar Ridge Augmentation:** In March 2007 the INFUSE® Bone Graft (Medtronic Sofamor Danek, Memphis, TN) was granted premarket approval from the FDA for use in oral surgical procedures, (i.e., sinus augmentation and localized alveolar ridge augmentation for defects associated with extraction sockets), as an alternative to autograft. According to the FDA, INFUSE Bone Graft is used to fill space where bone is needed in order to place endosseous dental implants. Dental implants should be placed if there is sufficient bone to stabilize them. When the sinus wall is thin, there is not enough bone to place dental implants. In a procedure known as sinus augmentation, a sinus graft is inserted into the floor of the sinus (i.e., the roof of the upper jaw). Dental implants can then be inserted and stabilized in the new sinus bone. The alveolar ridge of the jaw is the bone that surrounds the roots of the teeth. When a tooth is extracted, a socket remains which later heals; however, typically, previous height and width are not restored. Alveolar ridge augmentation is a procedure performed to increase bone volume, making treatment with dental implants possible.

The FDA notes the following contraindications to use for oral surgical procedures:

- in patients with an active infection at the operative site
- in patients who are pregnant
- in patients who are hypersensitive to rhBMP–2 or bovine type I collagen
- in an area where there was a tumor

Evidence in the published scientific literature evaluating rhBMP–2 for oral maxillofacial surgery consists of few published clinical trials (Esposito, et al., 2007; Boyne, et al., 2005; Fiorellini, et al., 2005; Jung, et l., 2003). Although the study results suggest that this technique may be a promising treatment option, the evidence in the published, peer-reviewed, scientific literature is insufficient to allow strong conclusions regarding the long-term effectiveness of rhBMP–2 for sinus augmentation and alveolar ridge augmentation. Published studies have been small in sample size, and data on long-term outcomes are lacking. Patient selection criteria are not well-defined. Some studies have indicated that rhBMP–2 is safe and enhances bone maturation. However, additional well-designed clinical trials assessing long-term health outcomes are needed to validate these results.

**RhBMP–7/ OP–1™ Putty**

A second type of human bone morphogenetic protein is rhBMP–7, marketed in the United States as OP–1™ Implant for use in healing fractures of the long bones, and OP–1™ Putty for use in spinal fusion. The FDA approved the OP–1 Implant and the OP–1 Putty for use in specifically-defined patients under a humanitarian device exemption (HDE).

**Posterolateral Lumbar Spinal Fusion:** The FDA granted HDE approval in April 2004 for the use of OP–1™ Putty (Stryker Biotech, Hopkinton, MA) for use as an alternative to autograft in compromised patients requiring revision posterolateral spinal fusion of the lower back. OP–1 Putty is made from a manufactured human protein powder and bovine collagen that is mixed with a saline solution and a thickening agent to form a putty-like material. During surgery, the putty is placed on each side of the spinal levels to be fused. The FDA approval specifies patient selection criteria as those who meet both of the following:

- failed previous spinal fusion surgery
- not candidates for autograft because of a condition such as osteoporosis, diabetes, or smoking

The use of the product is contraindicated in patients with the following conditions:

- allergy to OP–1 or collagen
- existing tumor, tumor removed at or near the fracture, or history of malignancy
- previous history of cancer
- skeletal immaturity
- pregnancy
The data presented to the FDA for consideration of approval is contained in the FDA Summary of Safety and Probable Benefit (FDA, 2004). Forty-eight patients with single-level degenerative lumbar spondylolisthesis and spinal stenosis received rhBMP–7 alone, rhBMP–7 combined with autograft, or autograft alone. The patients receiving rhBMP–7 alone demonstrated superior success, as evidenced by radiograph and clinical improvement, over those receiving autograft alone.

The FDA decision is based on the clinical data, as well as the following rationale provided in the approval summary: "When revision of a failed fusion is required, most patients are limited to either living with pain and altered function or repeating the original procedure with additional autologous bone, which may result in depletion of the bone stock and further risk to the patient. Allograft bone and bone graft substitutes are not considered feasible alternatives to autograft in revision surgery due to their lack of osteogenic potential. For certain patients, e.g., those with implanted leads, bone growth stimulators would not be considered as feasible options. OP–1 Putty has the potential to eliminate the risk and complications associated with these treatment alternatives while providing a feasible and beneficial alternative treatment.”

Some of the outcomes reported for osteoinductive properties and fusion rates are comparable to those of autograft, and the use of rhBMP–7 does avoid the need for autogenous bone graft harvest. Overall, a paucity of studies have assessed rhBMP–7 in spine fusion surgery (Delawi, et al., 2010; Vaccaro, et al., 2008; Kanayama, et al., 2006; Vaccaro, et al., 2004; Vaccaro, et al., 2003; Johnsson, et al., 2002). Limitations to these available studies such as use of combined materials, small sample size and short-term follow-up do not lead to formation of evidence-based conclusions regarding safety, efficacy and improved clinical outcomes. Additionally these trials evaluated primary fusion surgery and not revision surgery as mentioned in the HDE approval, and are therefore not in agreement with FDA limitations. Studies evaluating safety and efficacy of on-label use in the peer-reviewed published scientific literature are lacking. Other variables precluding generalizations include inconsistency with regard to instrumentation; some procedures were instrumented while others were not. Additional studies are needed to assess clinical outcomes.

**Fracture Repair:** The FDA gave HDE approval for the use of rhBMP–7 to treat nonunion of long bones. It is a powder that is mixed with normal saline to form a paste which is applied during surgery. The substance is marketed in the U.S. as OP–1™ Implant (Stryker Biotech, Hopkinton, MA).

The FDA approval indicates that the substance is appropriate for use in the surgical repair of long bone nonunion when both of the following patient selection criteria are met:

- autograft is not feasible
- alternative treatments have failed

The use of the product is contraindicated in patients with the following conditions:

- allergy to OP–1 or collagen
- existing tumor or tumor removed at or near the fracture or history of malignancy
- previous history of cancer
- skeletal immaturity
- pregnancy

Similar to posterolateral lumbar fusion surgery, studies evaluating the use of rhBMP–7 for nonunion of long bones are limited by small sample size and short term follow-up. Although there is some evidence of successful clinical outcomes resulting from the use of rhBMP–7 for the treatment of nonunion in the published scientific literature (Ronga, et al., 2006; Maniscalco, et al., 2002; Friedlaender, et al., 2001; Geesink, et al., 1999) evidence is insufficient to draw strong conclusions regarding safety and efficacy.

**Platelet Rich Plasma (PRP) for Bone Healing**
Platelet rich plasma (plasma having a platelet concentration above baseline) is an approach being investigated for the treatment of bone healing. PRP is also referred to as autologous platelet derived growth factor, platelet enriched plasma, platelet-rich concentrate, and autogenous platelet gel or platelet releasate. When activated in
the body, platelets release growth factors which accelerate healing, including platelet-derived growth factor, transforming growth factor beta (TGF-β) and insulin-like growth factor to name a few. It is hypothesized that a concentrated preparation of platelets, which contain higher concentrations of growth factors, may promote more rapid healing. Platelet concentrates are not osteoinductive since they do not include BMPs (Marx, 2004), although in theory they promote osteoblast proliferation and differentiation (Veillette, McKee, 2007). During the procedure, a small amount of the patient’s blood is drawn and centrifuged to separate red blood cells from the platelet-rich plasma. The platelet-rich plasma is then mixed with the patient’s bone graft material. Theoretically, the growth factors signal the local mesenchymal and epithelial cells to migrate, divide, and increase collagen and matrix synthesis increasing bone regeneration. Overexposure of cells to PRP yields many cells but limited differentiation of those cells into appropriate cell lines. It has been suggested that the inability to control differentiation is a reason to not use PRP for healing of tissue (Mehta, Watson, 2008).

Platelet concentration devices are approved by the FDA as part of the 510(k) approval process for preparation of platelet rich plasma. Examples of devices that are FDA approved include PCCS(TM) Platelet Concentrate Separation Kit (3i [Implant Innovations Inc.] and Magellan(TM) Autologous Platelet Separator System (Medtronic Perfusion Systems).

Currently, whether or not platelet rich plasma facilitates osteoinduction and improves clinical outcomes remains unproven in the published scientific literature. (Please refer to CIGNA Coverage Policy: Autologous Platelet-Derived Growth Factors [Platelet Rich Plasma] for further detail regarding autologous platelet derived growth factor).

U.S Food and Drug Administration (FDA)
The FDA classifies most orthobiologics (e.g., rhBMP–2, Osteoset, Grafton) as Class II devices. Many of the bone graft substitutes are approved through the 510(k) process and are based on a predicate device clearance although some require premarket approval (i.e., Class III devices). In addition, some of the bone graft materials are regulated as human tissue and do not require clinical trials or FDA approval for marketing, such as some of the DBM products and cell-based materials.

Humanitarian Device Exemption (HDE) was granted by the FDA for the OP-1 Implant and the OP-1 Putty, also referred to as rhBMP–7, for use in specifically defined patients (FDA, H010002, H020008). According to the FDA, a humanitarian use device (HUD) is a device that is intended to benefit patients by treating or diagnosing a disease or condition that affects fewer than 4,000 individuals in the United States per year. An HDE application is not required to contain the results of scientifically valid clinical investigations demonstrating that the device is effective for its intended purpose.

Ligament/Meniscus Reconstruction
The use of adjunctive treatments such as autologous platelet-derived growth factors (e.g., centrifuged platelet aggregates) have been utilized to assist in healing of tissues, however, there is insufficient evidence in the medical literature at this time, in particular with ACL/PCL reconstruction using allograft tissue or meniscal transplant, to support any improvement in health outcomes with the use of these adjunctive treatments.

Other options under investigation for meniscal regeneration and/or transplantation include tissue-engineered menisci, bioactive scaffolds (collagen meniscal implants, bioresorbable porous polyurethane), and synthetic devices (e.g., hydrogel) (Packer and Rodeo, 2009). Collagen meniscal implants have been proposed by some authors for filling defects of partial meniscectomy with functional repair tissue. Authors hypothesize the collagen meniscal implant may help prevent or delay the progression of osteoarthritis, protecting from degenerative joint disease. In addition, xenografts and meniscal prostheses are under investigation for use as an alternative approach to meniscal allograft transplantation (Verdonk, et al., 2007).

Autologous Platelet-derived Growth Factors (e.g., platelet rich plasma [PRP]): Platelet-rich plasma, derived from autologous blood, is being investigated for cartilage regeneration and for anterior ligament reconstruction. Theoretically, delivering high concentrations of growth factors, found in the platelet rich plasma, to focal areas may enhance healing, improve mechanical properties during the remodeling phase, and improve the rate of graft incorporation and maturation. One purported use involves autologous platelet-derived growth factors (e.g.,
centrifuged platelet aggregates, platelet rich plasma) with tendon and ligament repair. Nevertheless, the applicability for this use is controversial.

**U.S. Food and Drug Administration (FDA):** The systems used for preparing autologous platelet-derived growth factors are FDA approved under the 510(k) notification process. In general, the systems are approved to be used at the patient’s point of care and/or in a clinical laboratory to prepare autologous platelet-rich plasma (PRP)/platelet concentrate from the patient’s own blood.


**Meniscus Regeneration/Transplantation:** The meniscus is a crescent-shaped wedge of fibrocartilage located in the knee joint between the femoral condyle and tibial plateau. Small meniscal tears can be sutured, however, management of more severe meniscal injury involves arthroscopic or open surgery, often with meniscal allograft transplant. Other options under investigation for meniscal regeneration and/or transplantation include tissue-engineered menisci, bioactive scaffolds (collagen meniscal implants, bioresorbable porous polyurethane), and synthetic devices (e.g., hydrogel) (Packer and Rodeo, 2009). Collagen meniscal implants have been proposed by some authors for filling defects of partial meniscectomy with functional repair tissue. Authors hypothesize the collagen meniscal implant may help prevent or delay the progression of osteoarthritis, protecting from degenerative joint disease. In addition, xenografts and meniscal prostheses are under investigation for use as an alternative approach to meniscal allograft transplantation (Verdonk, et al., 2007).

**U.S. Food and Drug Administration (FDA):** Menaflex™ (ReGen Biologics, Inc., Hackensack, NJ), was granted a 510(k) approval from the FDA in December 2008. Menaflex is a resorbable collagen matrix regulated by the FDA as a Class II device. The collagen scaffold is used to reinforce weakened soft tissue and provides a resorbable scaffold that is replaced by the patient’s own tissue. According to the FDA, the scaffold was approved for the reinforcement and repair of soft tissue injuries of the medial meniscus (FDA, 2008); the device was not cleared for use in lateral meniscal injuries. However, in 2010 the FDA announced that the Menaflex device should not have been cleared for marketing in the U.S. and implemented a rescission. A rescission is an action by the FDA to revoke a marketing clearance later determined to be erroneous. The FDA concluded that the Menaflex device is intended to be used for different purposes and is technologically different from predicate devices (i.e., devices already on the market); these differences can affect the safety and effectiveness of the device.

**Literature review:** Evidence evaluating the safety and efficacy of collagen meniscal implants generally involve small patient populations. Some of the preliminary results are encouraging, suggesting meniscus regeneration occurs with an associated reduction in patient symptoms (Zaffagnini, et al., 2007). One prospective randomized trial (n=311) conducted by Rodkey et al. (2008) demonstrated the use of a collagen meniscus implant appeared safe, supported new tissue ingrowth and improved clinical outcomes (e.g., pain scores, Lysholm scores and patient assessment scores) in patients with chronic meniscal injury at an average follow-up of 59 months. The authors noted that patients who received the implant regained significantly more of their lost activity when compared to a group of patients who underwent repeat partial meniscectomy. A technology assessment conducted by the California Technology Assessment Forum (2010) concluded that the collagen meniscal implant for irreparable medial meniscus injury did not meet CTAF technology assessment criterion. The published evidence did not support improvement in health outcomes or that clinical improvement was attainable outside of the investigational setting. Although promising, long-term data supporting safety, efficacy and improved clinical outcomes, including prevention of osteoarthritis, are not yet available to support widespread use of this bioactive scaffold for meniscal regeneration.

There is a paucity of evidence in the peer-reviewed published scientific literature evaluating meniscal scaffolds and implants (Zaffagnini, et al., 2007; Rodkey et al., 2008; California Technology Assessment Forum, 2010). For other emerging technologies, much of the evidence is in the form of animal, cadaveric or short-term clinical trials and does not support safety and efficacy. Additionally there is no consensus opinion with regard to their widespread clinical application.
Use Outside of the US: Meniscal implant devices are available for use in countries outside the U.S. For example, Actifit™ (Orteq® LTD, United Kingdom), a biodegradable polyurethane scaffold designed to help repair meniscal tears, is currently approved for use in Europe. According to the manufacturer, NUsurface® Meniscus Implant (Active Implants® LLC, Memphis TN), a free-floating non-degradable polycarbonate-urethane device intended for total meniscal replacement, is also undergoing clinical trials in Europe, Israel, France, Germany, Belgium, the Netherlands, United Kingdom and Sweden.

Bone and/or Articular Cartilage Filler Materials

Synthetic Resorbable Polymers: Synthetic bone void fillers can be categorized into ceramics, polymers and composites. Ceramics are osteoconductive and are composed of calcium; total degradation time depends on the composition. Composite grafts combine osteoconductive matrix with bioactive agents that provide osteoinductive and osteogenic properties. Polymers are osteoconductive and when used with marrow could provide a biodegradable osteoinductive implant for repairing large defects. Synthetic bone void fillers have been proposed by some researchers as an alternative to allografting.

U.S. Food and Drug Administration (FDA): PolyGraft BGS (bone graft substitute), a resorbable bone void filler, was granted 510(k) marketing approval by the FDA in 2003 because it was considered to be substantially equivalent to another device already on the market (i.e., Wright Plaster of Paris Pellets [K963562] and ProOsteon 500R [K980817]). The device is a Class II device intended for filling bony voids or gaps caused by trauma or surgery that are not intrinsic to the stability of bony structure.

Literature review: Although synthetic resorbable polymers, such as PolyGraft, are available and have been proposed as bone graft substitute materials (Gardiner and Weitzel, 2007; Niederauer, et al., 2006), the available evidence for their use consists mainly of studies performed on animals. Human studies in the published scientific literature are limited and consist mainly of a few case reports and case series. Although some clinical outcomes are encouraging, poor clinical outcomes such as persistent pain, functional deficits and failure of graft incorporation have been reported and lend support to problems with biocompatibility when using synthetic implants for some individuals. Consequently, evidence in the medical literature is insufficient to support the potential value of synthetic resorbable polymers as an alternative to allograft or autograft for the repair of osteochondral defects.

Minced Juvenile Cartilage Allograft (DeNovo® NT Natural Tissue Graft [DeNovo® ET™ Engineered Tissue Graft [ISTO Technologies, Inc., St. Louis, MO, Zimmer, Inc., Warsaw IN]]): Filling defects with minced articular cartilage (autologous or allogeneic), is a single-stage procedure that is being investigated for cartilage repair. DeNovo® NT Natural Tissue Graft is a juvenile cartilage allograft tissue intended for the repair of articular cartilage defects (e.g., knee, ankle, hip, shoulder, elbow, great toe). The DeNovo NT Graft consists of particulated natural articular cartilage with living cells. Tissues are recovered from juvenile donor joints. The cartilage is manually minced to help with cell migration from the extracellular matrix and facilitate fixation. During implantation, the minced cartilage is mixed in a fibrin glue adhesive. According to the National Institutes of Health Clinical trials.gov studies are being conducted to evaluate long-term outcomes, including pain relief and improvement of function, for both knee and ankle cartilage repair.

DeNovo® ET™ Engineered Tissue Graft (i.e., RevaFlex™) is a scaffold free tissue-engineered juvenile cartilage graft proposed for the treatment of articular cartilage lesions. DeNovo ET uses juvenile articular cartilage cells applied to defects of the joint surface using a protein-based adhesive.

Other cartilage matrices under investigation include the Cartilage Autograft Implantation System (CAIS, Johnson and Johnson, Phase III trial) that purportedly harvests cartilage and disperses chondrocytes on a scaffold in a single-stage treatment and BioCartilage® (Arthrex, Naples, Florida) which consists of a micronized allogeneic cartilage matrix that is intended to provide a scaffold for microfracture.

U.S. Food and Drug Administration (FDA): DeNovo NT is classified as minimally manipulated allograft tissue and is therefore not subject to the FDA premarket approval process. The FDA requires that the manufacturers of human allograft products be registered. Currently DeNovo NT is registered on the FDA’s Human Cell and Tissue-Based Products (HCT/P) list. No listing could be found for DeNovo ET.
**Literature review:** Evidence in the peer-reviewed published scientific literature is insufficient to support the safety and efficacy of DeNovo ET or DeNovo NT.

**Professional Societies/Organizations**

In 2013 the American Orthopaedic Foot and Ankle Society (AOFAS, 2013) published a position statement regarding osteochondral transplantation for the treatment of osteochondral lesions of the talus. According to this position statement the AOFAS does not consider the procedure, using either autograft or allograft, experimental when the individual has failed non-operative management, particularly for large diameter lesions (>15 mm in diameter) and cystic lesions (i.e., cyst in subchondral bone).

The Washington State Health Care Authority technology assessment program published a technology assessment evaluating Osteochondral Allograft/Autograft Transplantation (2011). Regarding the evidence for the effectiveness of autograft OAT/mosaicplasty in the knee and ankle, there were substantial differences in patient populations, comparators, and outcome measures across all studies and given the high potential for bias, it was noted no firm conclusions could be drawn.

The American College of Rheumatology (ACR) Recommendations for the Medical Management of Osteoarthritis of the Hip and Knee (ACR, 2000) has noted that significant advances such as autologous chondrocyte transplantation, cartilage repair using mesenchymal stem cells, and autologous osteochondral plugs are being investigated; however, they do not recommend those procedures for the treatment of patients with osteoarthritis. There has been no update to the recommendations since the initial publication in 2000.

**Technology Assessments**

Technology assessments evaluating the safety and efficacy of bone graft substitutes in general were not found in the medical literature. Although the American Academy of Orthopaedic Surgeons does not have a formal position statement, the Orthopaedic Device Forum initially published a document addressing the use of bone graft substitutes in 2001 (Greenwald, et al., 2001). The forum noted at that time, and again in 2006 and 2008, that the currently marketed products vary in their composition and their claimed mechanisms of action—not all substitutes perform the same. Selection should be based on reasoned burdens of proof which include the examination of the product claims and whether or not they are supported by preclinical and human studies in site specific locations, where they are to be utilized in surgery. The AAOS noted it is imperative to appreciate the level of evidence claimed in the latter studies.

In 2010 the Agency for Healthcare Research and Quality (AHRQ) published a technology assessment evaluating on and off-label use of bone morphogenetic protein (AHRQ, 2010). A total of 41 articles, which included RCTs, nonrandomized comparative studies, and other observational studies, met inclusion criteria and were reviewed as part of the assessment. For on-label use, the evidence gave moderate support to clinical benefit from the use of rhBMP–2 for fusion of the lumbar-sacral spine, rhBMP–2 improved outcomes when used for the treatment of acute open tibial fractures, rhBMP–2 did not provide an advantage in prosthesis implantation and functional loading when used for sinus augmentation. The evidence was insufficient to evaluate the use rhBMP–7 for fusion of the spine. There was low strength evidence to support rhBMP–7 improved outcomes for recalcitrant long bone nonunion. Regarding off-label use, the strength of evidence that rhBMP–2 improved radiographic fusion success was moderate, however no conclusion could be drawn regarding the potential impact of off-label components on fusion success. The evidence was insufficient to draw conclusions regarding off-label use of rhBMP–7 in fusion of the lumbar spine. There was moderate support that off-label use of rhBMP–2 in anterior cervical spinal fusion increased cervical swelling and related complications. There was insufficient evidence to draw conclusions about radiographic fusion success or associated changes in neck disability scores.

Although there are no recent updates, several other technology assessments specifically evaluating rhBMP are available in the medical literature. A health technology assessment was conducted by Garrison et al. (2007) to assess the clinical- and cost- effectiveness of BMP for the treatment of spinal fusions and the healing of fractures compared to current standards of care under the National Health Service, England. All studies that reported on BMP for these indications were included; however, the authors focused primarily on evidence from RCTs because of the poor quality of data from the case series. The authors reviewed eight RCTs evaluating BMP for tibial fractures, one for scaphoid fractures, and 12 for spinal fusion. The authors noted several methodological weaknesses such as unreported randomization, incomparable baseline characteristics between groups, failure to
perform intention-to-treat analysis, to use independent blinded assessors and failure to report reasons for dropouts. In some studies, secondary outcomes were not measured and/or reported. Data indicated that BMP increased fracture union for patients with acute tibial fractures and found that high-dose BMP is more effective than a lower dose for open tibial fractures. The evidence supporting safety of BMP for scaphoid nonunion was limited. Evidence indicated that BMP-2 is more effective than autogenous bone graft for radiographic fusion in patients with single-level degenerative disc disease, and that BMP was associated with a shorter hospital stay and reduced operating time compared to autograft.

The California Technology Assessment Forum (CTAF) (Feldman, et al., 2005) reviewed literature to assess safety and effectiveness of rhBMP for spinal surgery and tibial fractures. The focus of the review was for rhBMP–2 for the promotion of bone fusion and to accelerate healing. The CTAF concluded that rhBMP–2 carried on a type-I collagen sponge meets CTAF criteria when used in conjunction with FDA- approved devices for the treatment of patients undergoing single-level spinal anterior lumbar interbody fusion for symptomatic single-level degenerative disc disease at L4–S1 of at least six months' duration that has not responded to nonoperative treatment.

In 2005, the Ontario Health Technology Advisory Committee published a report evaluating osteogenic protein–1 (OP–1) for long bone fracture nonunion. Based on level one evidence, the recommendation of the Committee stated that OP-1 was a reasonable alternative to autologous bone grafting in the treatment of long bone nonunions, and the decision to use it should be left to the discretion of treating physicians.

In 2004, the Ontario Health Technology Advisory published a report evaluating the safety and effectiveness of rhBMP (i.e., INFUSE) for spinal surgery as an alternative to autologous bone grafting. Their recommendations indicate that the Infuse device is safe. For spinal fusion, radiologic fusion occurs at a consistently faster rate among recipients of the BMP device than among recipients of autologous bone grafts. However, no differences in clinical outcomes were noted. Regardless of technique, improvements in pain and disability are reported by similar proportions of participants in all the arms of all the trials. At the time of the report, BMP devices for cervical fusion were not approved in Canada.

In 2003, the Washington Department of Labor and Industries conducted a technology assessment evaluating BMP for treatment of long bone fractures and for use in spinal fusion procedures. The authors reviewed several RCTs comparing BMP to autograft for the treatment of long bone fractures and concluded that patients with closed tibial fractures and patients with tibial nonunions had similar outcomes, regardless of treatment regimen. Patients who received BMP had shorter operative times and shorter hospital stays, although these results were not always statistically significant. Patients with BMP implants did not experience donor-site pain when compared to the autograft patients. Two case series that evaluated BMP for femoral nonunion had positive outcomes; however, the study did not have comparison groups. Additionally, RCTs of patients who underwent spinal fusion using BMP, when compared to autograft, had similar outcomes, regardless of treatment.

### Appendix 1 – Procedure to Coding Crosswalk

<table>
<thead>
<tr>
<th>Musculoskeletal Procedure/Orthobiologic</th>
<th>Intended Use (this list may not be all inclusive)</th>
<th>Application CPT/HCPCS Codes</th>
<th>Product HCPCS Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bioreosorbable porous polyurethane (bioactive/tissue engineered scaffold)</td>
<td>Meniscal regeneration/transplantation</td>
<td>29999</td>
<td>L8699</td>
</tr>
<tr>
<td>Collagen meniscal implant (bioactive/tissue engineered scaffold)</td>
<td>Meniscal regeneration/transplantation</td>
<td>29999 G0428</td>
<td>L8699</td>
</tr>
<tr>
<td>Meniscal prosthesis/total meniscus replacement</td>
<td>Meniscal regeneration/transplantation</td>
<td>29999</td>
<td>L8699</td>
</tr>
<tr>
<td>Xenograft</td>
<td>Meniscal regeneration/transplantation</td>
<td>29999</td>
<td>L8699</td>
</tr>
</tbody>
</table>
Juvenile cartilage allograft:
- DeNovo® NT Natural Tissue Graft Graft
- DeNovo® ET™ Engineered Tissue Graft Graft
- BioCartilage

Treatment of articular cartilage defects
23929, 24999, 27299, 27599, 28899, 29999
L8699

---

**Medicare Coverage Determinations**

<table>
<thead>
<tr>
<th>Contractor</th>
<th>Policy Name/Number</th>
<th>Revision Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCD</td>
<td>National No NCD</td>
<td></td>
</tr>
<tr>
<td>LCD</td>
<td>Local No LCD</td>
<td></td>
</tr>
</tbody>
</table>

Note: Please review the current Medicare Policy for the most up-to-date information.

---

**Coding/Billing Information**

Note: 1) This list of codes may not be all-inclusive.

2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

Most bone graft substitutes used to enhance bone healing do not have a specific CPT or HCPCS code to represent the material. However, there are specific CPT codes to differentiate by type of graft. For all other procedures, coverage will be considered based on the clinical indication and type of material for the procedure requested.

**Autograft, Allograft (non rhBMP-2), Synthetic (Ceramic/Polymer)**

Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>20900</td>
<td>Bone graft, any donor area; minor or small (eg, dowel or button)</td>
</tr>
<tr>
<td>20902</td>
<td>Bone graft, any donor area; major or large</td>
</tr>
<tr>
<td>20930</td>
<td>Allograft, morselized, or placement of osteopromotive material, for spine surgery only (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>20931</td>
<td>Allograft, structural, for spine surgery only (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>20936</td>
<td>Autograft for spine surgery only (includes harvesting the graft); local (eg, ribs, spinous process, or laminar fragments) obtained from same incision (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>20937</td>
<td>Autograft for spine surgery only (includes harvesting the graft); morselized (through separate skin or fascial incision) (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>20938</td>
<td>Autograft for spine surgery only (includes harvesting the graft); structural, bicortical or tricortical (through separate skin or fascial incision) (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>20999</td>
<td>Unlisted procedure, musculoskeletal system, general</td>
</tr>
<tr>
<td>27899</td>
<td>Unlisted procedure, leg or ankle</td>
</tr>
<tr>
<td>HCPCS Codes</td>
<td>Description</td>
</tr>
<tr>
<td>-------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>C9359</td>
<td>Porous purified collagen matrix bone void filler (Integra Mozaik osteoconductive scaffold putty, Integra Os osteoconductive scaffold putty), per 0.5 cc</td>
</tr>
<tr>
<td>C9362</td>
<td>Porous purified collagen matrix bone void filler (Integra Mozaik osteoconductive scaffold strip), per 0.5 cc</td>
</tr>
<tr>
<td>L8699</td>
<td>Prosthetic implant, not otherwise specified</td>
</tr>
</tbody>
</table>

**Factor-based (rhBMP-2)**

Considered Medically Necessary when criteria in the applicable policy statements listed above are met and when used to report rhBMP–2 utilized in combination with a fusion device for single-level anterior interbody lumbar fusion surgery or for surgical repair of acute, open tibial fracture:

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>20930</td>
<td>Allograft, morselized, or placement of osteopromotive material, for spine surgery only (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>20999</td>
<td>Unlisted procedure, musculoskeletal system, general</td>
</tr>
<tr>
<td>27899</td>
<td>Unlisted procedure, leg or ankle</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>L8699</td>
<td>Prosthetic implant, not otherwise specified</td>
</tr>
</tbody>
</table>

Considered Experimental/Investigational/Unproven when used to report rhBMP–2 for ALL other indication indications including spinal fusions other than single-level anterior spinal fusions, as an alternative or adjunct treatment for sinus augmentation and/or localized alveolar ridge augmentation, or for the treatment of cervical spinal conditions:

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>20930</td>
<td>Allograft, morselized, or placement of osteopromotive material, for spine surgery only (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>21208</td>
<td>Osteoplasty, facial bones; augmentation (autograft, allograft, or prosthetic implant)</td>
</tr>
<tr>
<td>21210</td>
<td>Graft, bone; nasal, maxillary or malar areas (includes obtaining graft)</td>
</tr>
<tr>
<td>21499</td>
<td>Unlisted musculoskeletal procedure, head</td>
</tr>
<tr>
<td>31299</td>
<td>Unlisted procedure, accessory sinuses</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CDT®** Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>D4263</td>
<td>Bone replacement graft - first site in quadrant</td>
</tr>
<tr>
<td>D4264</td>
<td>Bone replacement graft - each additional site in quadrant</td>
</tr>
<tr>
<td>D4265</td>
<td>Biologic materials to aid in soft and osseous tissue regeneration</td>
</tr>
<tr>
<td>D7950</td>
<td>Osseous, osteoperiosteal, or cartilage graft of the mandible or maxilla—autogenous or nonautogenous, by report</td>
</tr>
<tr>
<td>D7951</td>
<td>Sinus augmentation with bone or bone substitutes</td>
</tr>
<tr>
<td>D7953</td>
<td>Bone replacement graft for ridge preservation– per site</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>L8699</td>
<td>Prosthetic implant, not otherwise specified</td>
</tr>
</tbody>
</table>
Considered Experimental/Investigational/Unproven when used to report rhBMP-7 (i.e., OP-1™) for ALL indications:

<table>
<thead>
<tr>
<th>CPT®* Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>20930</td>
<td>Allograft, morselized, or placement of osteopromotive material, for spine surgery only (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>20999</td>
<td>Unlisted procedure, musculoskeletal system, general</td>
</tr>
<tr>
<td>23929</td>
<td>Unlisted procedure, shoulder</td>
</tr>
<tr>
<td>24999</td>
<td>Unlisted procedure, humerus or elbow</td>
</tr>
<tr>
<td>25999</td>
<td>Unlisted procedure, forearm or wrist</td>
</tr>
<tr>
<td>27599</td>
<td>Unlisted procedure, femur or knee</td>
</tr>
<tr>
<td>27899</td>
<td>Unlisted procedure, leg or ankle</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>L8699</td>
<td>Prosthetic implant, not otherwise specified</td>
</tr>
</tbody>
</table>

Considered Experimental/Investigational/Unproven when used to report human amniotic membrane bone graft substitute, cell-based/mesenchymal stem cell used as bone graft substitute, factor-based, synthetic or allograft substitute following autograft harvest for iliac crest reconstruction (i.e., back fill grafting of an iliac crest donor site):

<table>
<thead>
<tr>
<th>CPT®* Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>20930</td>
<td>Allograft, morselized, or placement of osteopromotive material, for spine surgery only (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>20999</td>
<td>Unlisted procedure, musculoskeletal system, general</td>
</tr>
<tr>
<td>27299</td>
<td>Unlisted procedure, pelvis or hip joint</td>
</tr>
<tr>
<td>27599</td>
<td>Unlisted procedure, femur or knee</td>
</tr>
<tr>
<td>29999</td>
<td>Unlisted procedure, arthroscopy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>L8699</td>
<td>Prosthetic implant, not otherwise specified</td>
</tr>
</tbody>
</table>

Considered Experimental/Investigational/Unproven when used to report bone marrow aspirate processed to concentrate growth factors:

<table>
<thead>
<tr>
<th>CPT®* Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>20939</td>
<td>Bone marrow aspiration for bone grafting, spine surgery only, through separate skin or fascial incision (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>38232</td>
<td>Bone marrow harvesting for transplantation; autologous</td>
</tr>
<tr>
<td>38241</td>
<td>Hematopoietic progenitor cell (HPC); autologous transplantation</td>
</tr>
</tbody>
</table>

Considered Experimental/Investigational/Unproven for allograft bone graft substitutes used exclusively as stand-alone stabilization devices for fusion (e.g., TruFuse® for isolated facet fusion, NuFix™ for isolated facet fusion, BacFast® HD for isolated facet fusion):

<table>
<thead>
<tr>
<th>CPT®* Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0219T</td>
<td>Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; cervical</td>
</tr>
</tbody>
</table>
**CPT® Codes** | **Description**
---|---
0220T | Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; thoracic

**CPT® Codes** | **Description**
---|---
0221T | Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; lumbar

**CPT® Codes** | **Description**
---|---
0222T | Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; each additional vertebral segment (List separately in addition to code for primary procedure)

**HCPCS Codes** | **Description**
---|---
L8699 | Prosthetic implant, not otherwise specified

**Ligament/Meniscus Reconstruction**

Considered Experimental/Investigational/Unproven when used alone or as part of a ligament or meniscus reconstruction, regeneration, or transplantation are used to report bioactive scaffolds (e.g., collagen meniscal implants), bioresorbable porous polyurethane, meniscal prosthesis, tissue engineered menisci, or xenograft:

**CPT® Codes** | **Description**
---|---
29999 | Unlisted procedure, arthroscopy

**HCPCS Codes** | **Description**
---|---
G0428 | Collagen meniscus implant procedure for filling meniscal defects (e.g., CMI, collagen scaffold, menaflex)

**Bone Filler Materials**

Considered Experimental/Investigational/Unproven when synthetic resorbable polymers (e.g., PolyGraft™ BGS, TruFit® [cylindrical plug], TruGraft™ [granules]); juvenile cartilage allograft tissue implantation (e.g., DeNovo® NT Natural Tissue Graft, DeNovo® ET™ Engineered Tissue Graft); or decellularized osteochondral allograft implant (e.g., Chondrofix® Osteochondral Allograft) are used to report the treatment of articular cartilage defects:

**CPT® Codes** | **Description**
---|---
23929 | Unlisted procedure, shoulder
24999 | Unlisted procedure, humerus or elbow
27299 | Unlisted procedure, pelvis or hip joint
27599 | Unlisted procedure, femur or knee
27899 | Unlisted procedure, leg or ankle
28899 | Unlisted procedure, foot or toes
29999 | Unlisted procedure, arthroscopy

**HCPCS Codes** | **Description**
---|---
L8699 | Prosthetic implant, not otherwise specified

**Current Dental Terminology (CDT) ©2020 American Dental Association: Chicago, IL.
References


30. Campbell KA, Saltzman BM, Mascarenhas R, Khair MM, Verma NN, Bach BR Jr, Cole BJ. Does intra-articular platelet-rich plasma injection provide clinically superior outcomes compared with other therapies


